Table 1.
Characteristics of studies included in the systematic review
| Author Year | Country | Premedication | PPI administration of ESD day | Follow-up endoscopy | Patients number | Age ±SD | Gender M/F | Post-ESD bleeding (%) | Gastric pH measurement | Mean pH ±SD |
|---|---|---|---|---|---|---|---|---|---|---|
| Watanabe | Japan | LPZ 30 mg o.d. 7 days before ESD | Oral LPZ 30 mg | day 7, 56 | 51 | 72.5 ± 9.1 | 37/14 | 0 (0%) | Collecting gastric juice | 7.5 ± 0.7 |
| 2006 | No treatment | Oral LPZ 30 mg after ESD | 47 | 70.1 ± 8.0 | 37/10 | 3 (6.4%) | during ESD | 5.1 ± 1.4 | ||
| Ono | Japan | OPZ 20 mg o.d. 1 day before ESD | iv OPZ 20 mg before and after ESD | day 1, 7, 28 | 81 | 70.5 ± 8.3 | 51/30 | 6 (7.4%) | Collecting gastric juice | 7.3 ± 0.6 |
| 2009 | No treatment | iv OPZ 20 mg after ESD | 74 | 70.2 ± 9.1 | 60/14 | 6 (8.1%) | during ESD | 5.6 ± 3.7 | ||
| Baeg | Korea | RPZ 20 mg b.i.d. 5 days before ESD | iv PPZ 40 mg 2h before ESD | day 1, 30 | 45 | 59 ± 8.9 | 24/21 | 3 (6.7%) | 48-h pH monitoring | 6.7 ± 1.7 |
| 2014 | Placebo | iv PPZ 40 mg 2h before ESD | 53 | 58 ± 10 | 42/11 | 3 (5.7%) | after ESD | 6.5 ± 1.3 | ||
| Hikichi | Japan | RPZ 20 mg o.d. 3 days before ESD | oral RPZ 20 mg | day 7, 56 | 24 | 73.3 ± 7.8 | 18/6 | 0 (0%) | Collecting gastric juice | 7.2 ± 0.6 |
| 2014 | No treatment | oral RPZ 20 mg 7-8 h before ESD | 31 | 70.4 ± 9.0 | 21/10 | 1 (3.2%) | during ESD | 6.5 ± 1.1 |
ESD: endoscopic submucosal dissection; PPI: proton pump inhibitor, LPZ: lansoprazole, OPZ: omeprazole, PPZ: pantprazole, RPZ: rabeprazole; iv: intravenous.
Follow-up endoscopy: the days after the ESD.